Abstracts Archive - Page 1032 of 2607 - ACR Meeting Abstracts

Abstract Number: 1378 • 2019 ACR/ARP Annual Meeting
High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
Vibeke Strand¹, Jerome Msihid ², Toshio Kimura ³, Anita Boyapati ³, Gregory St John ⁴ and Wenhui Wei ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Sanofi, Chilly-Mazarin, France, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA) and is elevated in serum and synovial fluid of RA patients. However,…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting
Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry
Robin Dore¹, Jenya Antonova ², Leslie Harrold ³, Lawrence Chang ², Emily Scherer ⁴, Angel Cronin ⁵, Kelechi Emeanuru ⁵ and Joel Kremer ⁶, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC, Cambridge, MA, ⁵Corrona, LLC, Waltham, MA, ⁶Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…
Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting
High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis
Jun Inamo¹, Yuko Kaneko ², Jun Kikuchi ³ and Tsutomu Takeuchi ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
Abstract Number: 1382 • 2019 ACR/ARP Annual Meeting
The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients
Jacob Greenmyer ¹, John Stacy ¹, James Beal ², Abe Sahmoun ² and Erdal Diri¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Glucocorticoids (GCs) are commonly used in RA patients as remission induction monotherapy or as bridging therapy when starting DMARD/biologic therapy. Despite the ubiquity of…
Abstract Number: 1383 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study
Frank Buttgereit¹, J. Michael Nebesky ², Gerd Burmester ³, Corrado Bernasconi ², Markus R. John ² and Marc Y. Donath ⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴University Hospital Basel, Basel, Switzerland
Background/Purpose: Systemic glucocorticoids (GCs) are used to treat serious inflammatory diseases but are associated with adverse events. Guidelines recommend tapering GCs to the lowest possible…
Abstract Number: 1384 • 2019 ACR/ARP Annual Meeting
Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort
Kathleen M Andersen¹, Orit Schieir ², Marie-France Valois ³, Susan J. Bartlett ⁴, Louis Bessette ⁵, Gilles Boire ⁶, Glen Hazlewood ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Diane Tin ¹¹, Carter Thorne ¹², Vivian Bykerk ¹³ and Canadian Early Arthritis Cohort (CATCH) Investigators ¹⁴, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ²University of Toronto, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Laval University, Quebec City, QC, Canada, ⁶Sherbrooke University, Sherbrooke, QC, Canada, ⁷University of Calgary, Calgary, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, Canada, ¹²Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Hospital for Special Surgery, New York City, NY, ¹⁴Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Synthetic glucocorticoids (steroids) are recommended for and commonly used in rheumatoid arthritis (RA) as initial “bridge therapy”, acting to rapidly reduce the inflammatory response…
Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Mochihito Suzuki¹, Toshihisa Kojima ², Nobunori Takahashi ², Shuji Asai ² and Naoki Ishiguro ², ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
Abstract Number: 1386 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study
Leslie Harrold¹, Ying Shan ², Sabrina Rebello ², Lin Guo ², Sean Connolly ³, Joe Zhuo ³, Sheila Kelly ³ and Thomas Lehman ³, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Corrona, LLC, Waltham, MA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: In a US national observational study conducted in a clinical practice setting, patients who were positive (+) for anti-cyclic citrullinated peptide (CCP) antibodies at…
Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Jeffrey Curtis¹, Daniel Aletaha ², Gerd Burmester ³, Kerri Ford ⁴, Hubert van Hoogstraten ⁵, Henry Leher ⁶, Karthinathan Thangavelu ⁷ and Vivian Bykerk ⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of Vienna, Vienna, Austria, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁷Sanofi Genzyme, Boston, MA, ⁸Hospital for Special Surgery, New York City, NY
Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…
Abstract Number: 1388 • 2019 ACR/ARP Annual Meeting
The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM
Qian Xia ¹, Xue Han², Ying Bao ¹, Vardhaman Patel ³, Varshini Rajagopalan ⁴ and Francis Lobo ², ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Bristol-Myers Squibb, New York City, NY, ⁴Mu-Sigma, Bengaluru, India
Background/Purpose: Type 2 diabetes mellitus (T2DM)-related complications are costly, and there is lack of information regarding the comparative impact of target disease-modifying anti-rheumatic drugs (tDMARDs)…
Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Xue Han¹, Joshua Bryson ¹, David C Crosby ¹, Michael Evans ² and Gabriela Schmajuk ³, ¹Bristol-Myers Squibb, Princeton, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
Abstract Number: 1390 • 2019 ACR/ARP Annual Meeting
Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels
Silvia Piantoni¹, Michele Boldini ¹, Rajesh Kumar ¹, Emirena Garrafa ¹, Chiara Bazzani ², Micaela Fredi ³, Ilaria Cavazzana ¹, Angela Tincani ³ and Franco Franceschini ³, ¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: Carbamylation is a non-enzymatic irreversible post-translational modification of proteins. The presence of anti-carbamylated protein antibodies (anti-CarP) has been observed in rheumatoid arthritis (RA). In…
Abstract Number: 1391 • 2019 ACR/ARP Annual Meeting
Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study
Patryk Drobinski¹, Anne Bay-Jensen ², Morten Karsdal ³ and Anne Siebuhr ⁴, ¹University of Copenhagen/Nordic Bioscience, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Copenhagen, Denmark, ⁴Nordic Bioscience, Herlev
Background/Purpose: Response to treatments in Rheumatoid Arthritis (RA) is assessed by symptomatic changes, such as ACR-response and DAS28. However, such assessments do not provide information…
Abstract Number: 1392 • 2019 ACR/ARP Annual Meeting
The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes
Grigor Abelian¹, Sheng Gao ², Yash Gandhi ¹, Blisse Vakkalagadda ¹, Vidya Perera ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The purpose of this investigation was to characterize the relationship between systemic exposure of abatacept and measures of target engagement to further support dosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].